Immatics to highlight ACTengine program updates at SITC

By The Science Advisory Board staff writers

November 1, 2021 -- Immatics plans to offer an update on its ACTengine IMA203 trial at the upcoming Society for Immunotherapy of Cancer (SITC) 2021 annual meeting in Washington, DC, November 12-13.

The company's ACTengine is a next-generation CD8ab T-cell receptor T-cell (TCR-T) approach used to develop T cell-redirecting cancer immunotherapies. The approach uses a patient's own T cells that are genetically engineered to express a novel, proprietary T-cell receptor directed against a defined cancer target. The modified T cells are then reinfused into the patient to attack the tumor, an approach also known as TCR-T.

The update will be delivered by Dr. Martin Wermke of the University Hospital Carl Gustav Carus in Dresden, Germany, in a presentation titled "Safety and Anti-Tumor Activity of TCR-Engineered Autologous, PRAME-Directed T Cells Across Multiple Advanced Solid Cancers at Low Doses," according to Immatics.

A second presentation delivered by the company's director of process development, Mamta Kalra, PhD, will update attendees on the company's next-generation CD8ab TCR-T approach, it said.

Copyright © 2021

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.